MiMedx announces launch of EPIXPRESS

MiMedx (MDXG) Group announced the launch of EPIXPRESS, the Company’s newest addition to its portfolio of AWC solutions. EPIXPRESS expands MIMEDX’s PURION-processed placental allograft offering aimed at helping clinicians treat acute and chronic, hard-to-heal wounds. Like EPIEFFECT, EPIXPRESS is a lyophilized product, and features a thick, tri-layer configuration. Additionally, EPIXPRESS adds fenestrations to the sheet configurations to help with fluid movement. EPIXPRESS can be used on a wide range of common conditions, such as diabetic foot ulcers and venous leg ulcers, and other wound types, including those where the need exists to secure the graft in place with sutures. In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.